INTUITIVE SURGICAL INC (IUI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:IUI1 - US46120E6023 - Common Stock
489.2 EUR
-0.3 (-0.06%)
IUI1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 62 industry peers in the Health Care Equipment & Supplies industry. IUI1 gets an excellent profitability rating and is at the same time showing great financial health properties. IUI1 is valued quite expensively, but it does show have an excellent growth rating. This makes IUI1 very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year IUI1 was profitable.
IUI1 had a positive operating cash flow in the past year.
IUI1 had positive earnings in each of the past 5 years.
IUI1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IUI1 (14.19%) is better than 91.94% of its industry peers.
The Return On Equity of IUI1 (16.12%) is better than 83.87% of its industry peers.
IUI1 has a Return On Invested Capital of 11.69%. This is amongst the best in the industry. IUI1 outperforms 85.48% of its industry peers.
IUI1 had an Average Return On Invested Capital over the past 3 years of 9.53%. This is in line with the industry average of 9.74%.
The 3 year average ROIC (9.53%) for IUI1 is below the current ROIC(11.69%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROIC | 11.69% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
1.3 Margins
Looking at the Profit Margin, with a value of 28.58%, IUI1 belongs to the top of the industry, outperforming 98.39% of the companies in the same industry.
IUI1's Profit Margin has declined in the last couple of years.
IUI1 has a Operating Margin of 29.44%. This is amongst the best in the industry. IUI1 outperforms 98.39% of its industry peers.
IUI1's Operating Margin has declined in the last couple of years.
The Gross Margin of IUI1 (66.38%) is better than 72.58% of its industry peers.
In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% |
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IUI1 is creating some value.
The number of shares outstanding for IUI1 has been increased compared to 1 year ago.
Compared to 5 years ago, IUI1 has more shares outstanding
IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
There is no outstanding debt for IUI1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | N/A |
ROIC/WACC1.33
WACC8.78%
2.3 Liquidity
A Current Ratio of 4.97 indicates that IUI1 has no problem at all paying its short term obligations.
With an excellent Current ratio value of 4.97, IUI1 belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
A Quick Ratio of 4.20 indicates that IUI1 has no problem at all paying its short term obligations.
IUI1's Quick ratio of 4.20 is amongst the best of the industry. IUI1 outperforms 96.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 28.12% over the past year.
IUI1 shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.48% yearly.
Looking at the last year, IUI1 shows a very strong growth in Revenue. The Revenue has grown by 22.18%.
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
3.2 Future
Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.47% on average per year.
IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.12% yearly.
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.47%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 66.74 indicates a quite expensive valuation of IUI1.
IUI1's Price/Earnings is on the same level as the industry average.
IUI1 is valuated expensively when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 57.92, the valuation of IUI1 can be described as expensive.
IUI1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 70.97% of the companies in the same industry.
IUI1's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.74 | ||
| Fwd PE | 57.92 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 66.13% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IUI1 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 89.72 | ||
| EV/EBITDA | 56.64 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IUI1 does not grow enough to justify the current Price/Earnings ratio.
IUI1 has an outstanding profitability rating, which may justify a higher PE ratio.
IUI1's earnings are expected to grow with 15.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.32
PEG (5Y)5.81
EPS Next 2Y16.35%
EPS Next 3Y15.9%
5. Dividend
5.1 Amount
IUI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IUI1 (12/30/2025, 7:00:00 PM)
489.2
-0.3 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners88.16%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap173.42B
Revenue(TTM)9.61B
Net Income(TTM)2.75B
Analysts78
Price Target523.6 (7.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)11.61%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)13.53%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)11%
EPS beat(12)11
Avg EPS beat(12)7.6%
EPS beat(16)13
Avg EPS beat(16)5.75%
Revenue beat(2)2
Avg Revenue beat(2)2%
Min Revenue beat(2)1.84%
Max Revenue beat(2)2.17%
Revenue beat(4)4
Avg Revenue beat(4)2.55%
Min Revenue beat(4)1.09%
Max Revenue beat(4)5.12%
Revenue beat(8)5
Avg Revenue beat(8)1.17%
Revenue beat(12)6
Avg Revenue beat(12)0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.31%
PT rev (1m)-1.93%
PT rev (3m)4.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.25%
EPS NY rev (1m)0.16%
EPS NY rev (3m)5.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.69%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)1.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 66.74 | ||
| Fwd PE | 57.92 | ||
| P/S | 21.2 | ||
| P/FCF | 89.72 | ||
| P/OCF | 68.83 | ||
| P/B | 11.96 | ||
| P/tB | 12.21 | ||
| EV/EBITDA | 56.64 |
EPS(TTM)7.33
EY1.5%
EPS(NY)8.45
Fwd EY1.73%
FCF(TTM)5.45
FCFY1.11%
OCF(TTM)7.11
OCFY1.45%
SpS23.08
BVpS40.91
TBVpS40.08
PEG (NY)3.32
PEG (5Y)5.81
Graham Number82.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| ROCE | 16.61% | ||
| ROIC | 11.69% | ||
| ROICexc | 23.14% | ||
| ROICexgc | 24.12% | ||
| OM | 29.44% | ||
| PM (TTM) | 28.58% | ||
| GM | 66.38% | ||
| FCFM | 23.63% |
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)9.53%
ROIC(5y)9.27%
ROICexc(3y)14.41%
ROICexc(5y)14.87%
ROICexgc(3y)15.07%
ROICexgc(5y)15.72%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexgc growth 3Y-7.59%
ROICexgc growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 111.36% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.84% | ||
| Profit Quality | 82.69% | ||
| Current Ratio | 4.97 | ||
| Quick Ratio | 4.2 | ||
| Altman-Z | N/A |
F-Score8
WACC8.78%
ROIC/WACC1.33
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)28.12%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%30.43%
EPS Next Y20.12%
EPS Next 2Y16.35%
EPS Next 3Y15.9%
EPS Next 5Y15.47%
Revenue 1Y (TTM)22.18%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%22.91%
Revenue Next Year21.32%
Revenue Next 2Y18.09%
Revenue Next 3Y16.5%
Revenue Next 5Y14.12%
EBIT growth 1Y36.82%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year45.96%
EBIT Next 3Y24.75%
EBIT Next 5Y20.46%
FCF growth 1Y80.69%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y46.32%
OCF growth 3Y4.95%
OCF growth 5Y8.61%
INTUITIVE SURGICAL INC / IUI1.DE FAQ
Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?
ChartMill assigns a fundamental rating of 6 / 10 to IUI1.DE.
Can you provide the valuation status for INTUITIVE SURGICAL INC?
ChartMill assigns a valuation rating of 2 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.
Can you provide the profitability details for INTUITIVE SURGICAL INC?
INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 8 / 10.
Can you provide the financial health for IUI1 stock?
The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 7 / 10.